199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

T Yau,L Rimassa,A.-L Cheng,J.-W Park,F Braiteh,A Chaudhry,F Benzaghou,P Thuluvath,S Hazra,S Milwee,B Tan,R Sinha,Z.K Kayali,A.X Zhu,R.K Kelley

doi:10.1093/annonc/mdz422.075

199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

T Yau, L Rimassa + Show 13 more

Open Access

https://doi.org/10.1093/annonc/mdz422.075

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Queen Mary Hospital, National Taiwan University, Massachusetts General Hospital

#Merck Serono #Ono Pharmaceutical + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Full Text